Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Ann Surg Oncol. 2017 Mar 17;24(8):2161–2167. doi: 10.1245/s10434-017-5844-0

Figure 1. Toxicity associated with the combination of GP2+GM-CSF vaccine and trastuzumab.

Figure 1

(A) Local and systemic toxicity depicted as the percentage of patients in whom their highest grade toxicity was the designated grade. No grade 3 or 4 local toxicity was observed. (B) Results of LVEF prior to starting treatment with the GP2+GM-CSF vaccine and trastuzumab as well as during treatment as assessed per study protocol. The median ejection fraction (solid black line) did not change during the course of treatment.